New pharma guidelines: No ghostwriting, more public info

Wall Street Journal Health Blog, October 1, 2009

Clinical trial guidelines from the drug industry trade group PhRMA, go into effect Oct. 1. They include guidelines that basically ban ghostwriting of reports and stipulate that a doctor who has an ownership stake in a drug cannot be a clinical investigator in a trial of that drug. The guidelines are purely voluntary, however.